semaglutide cardiac effects SELECT: Glucagon-like peptide-1 receptor agonist in obese patients with cardiovascular disease in the absence of diabetes Common And Rare Side Effects – ACC guidance on obesity as

Well, before we wrap up, it's very clear the impact you've had has been profound, not just obviously at Novo Nordisk, but for the world of advancing health and medicine

compared GLP-1 agonists to other hypoglycemic agents, including metformin, sulfonylureas, thiazolidinediones, meglitinides, gliptins, and SGLT2 inhibitors

Novo Nordisk initiated large clinical trials to evaluate semaglutide, a drug initially developed for diabetes, in individuals with early Alzheimers disease (van der Flier Wiesje M

Its currently in Phase 3 clinical trials as part of Amgens MARITIME program, which is the final stage of testing before a company can apply for FDA approval

Karami M, Almaghrabi S, Banasr O, Hussein K (2025) Serum selenium levels and their relationship with insulin resistance in individuals with polycystic ovary syndrome